SCHEMBL3777366

SCHEMBL3777366

CCC(C)N1CCN(C(=O)CN2CCN(c3cc(Cl)ccc3OC)CC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
LMNA P02545 5/20 0.49
POLB P06746 2/20 0.49
MAPT P10636 1/20 0.49
TACR3 P29371 1/20 0.48
CYP2C9 P11712 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
MAPK1 P28482 1/20 0.46
HTR3E A5X5Y0 1/20 0.46
HTR3B O95264 1/20 0.46
HTR3A P46098 1/20 0.46
HTR3D Q70Z44 1/20 0.46
HTR3C Q8WXA8 1/20 0.46
F10 P00742 1/20 0.45
DPP4 P27487 1/20 0.45
MEN1 O00255 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3765119 0.92 KDM4E (0.52) KDM4EALDH1A1TDP1LMNAPOLB
SCHEMBL3768311 0.88 USP2 (0.57) KDM4EALDH1A1LMNAMAPTMEN1
SCHEMBL3763274 0.82 ALDH1A1 (0.51) KDM4EALDH1A1TDP1LMNAPOLB
SCHEMBL3765826 0.82 LMNA (0.53) KDM4EALDH1A1LMNAPOLBMAPT
SCHEMBL3772008 0.82 CCR1 (0.59)
SCHEMBL3767262 0.82 SMN1; SMN2 (0.67) ALDH1A1LMNAPOLBMAPTMEN1
SCHEMBL22892259 0.81 LMNA (0.59) ALDH1A1LMNAPOLBMAPTTACR3
SCHEMBL3780583 0.81 MEN1 (0.69) ALDH1A1LMNAMAPTMAPK1MEN1
SCHEMBL3762896 0.81 KDM4E (0.52) KDM4EALDH1A1TDP1LMNAPOLB
SCHEMBL3769777 0.81 KDM4E (0.52) KDM4EALDH1A1TDP1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KDM4E 534/4885ALDH1A1 1210/4885TDP1 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.